ICON

Patients

Outcome measures: Patients beyond endpoints

Pharmaceutical companies face increasing pressure to demonstrate not only the efficacy of their treatments, but also the impact of these treatments on patients' lives.

Digital

Measuring-the-cost-effectiveness-of-vaccines-DeepDive

How cost-effective are infectious disease vaccines?

Cost-effectiveness modelling is a powerful tool in understanding the value health interventions can bring to populations.

R&D

Using cross-functional teams to develop a product’s value st...

Tanya Brinsden, senior VP of operations at ICON Global Medical Communications and Pubs Hub, Jessica Cherian, VP of content and strategic services at ICON Market Access and Reimbursement, an

Deep Dive

Recruiting patients to increase diversity & inclusion in cli...

More so now than ever, the inclusion of more diverse, and often more relevant, study populations is gathering momentum within the clinical trial community.

Sales & Marketing

Navigating the patient maze – pharma’s evolving challenge

Pharma companies are embracing patient centricity in drug development more than ever before.

Views & Analysis

Lessons from the first generation of cell and gene oncology ...

Advances in cell and gene science are paving the way for transformative cancer treatments, but there are still many complexities in delivering clinical trials for these therapies.